[caption id="attachment_71306" align="aligncenter" width="500"]
Freepix image[/caption]
Are you still battling acne in your 30s, 40s, or beyond? Adult acne presents unique challenges that differ from adolescent breakouts, manifesting as inflammatory papules, pustules, comedones, and sometimes painful cystic lesions along the jawline, chin, and lower face. Hormonal fluctuations, stress-induced cortisol elevation, and compromised skin barrier function create a complex treatment landscape requiring targeted interventions. Dermatologists approach adult acne through combination therapies addressing both active lesions and underlying triggers while preventing post-inflammatory hyperpigmentation common in mature skin.
If you’re struggling with persistent acne that overlaps with sensitivity or eczema, consulting the best dermatologist in Singapore for eczema can help you receive a more holistic and tailored approach — balancing acne control with skin barrier repair for long-term skin health.
Freepix image[/caption]
Are you still battling acne in your 30s, 40s, or beyond? Adult acne presents unique challenges that differ from adolescent breakouts, manifesting as inflammatory papules, pustules, comedones, and sometimes painful cystic lesions along the jawline, chin, and lower face. Hormonal fluctuations, stress-induced cortisol elevation, and compromised skin barrier function create a complex treatment landscape requiring targeted interventions. Dermatologists approach adult acne through combination therapies addressing both active lesions and underlying triggers while preventing post-inflammatory hyperpigmentation common in mature skin.
If you’re struggling with persistent acne that overlaps with sensitivity or eczema, consulting the best dermatologist in Singapore for eczema can help you receive a more holistic and tailored approach — balancing acne control with skin barrier repair for long-term skin health.
Dr. Serena Guo[/caption]
Serena Jingchuan Guo, MD PhD
Assistant Professor
Department of Pharmaceutical Outcomes and Policy
University of Florida College of Pharmacy
[caption id="attachment_71231" align="alignleft" width="125"]
Dr. Hao Dai[/caption]
Hao Dai, PhD
Postdoctoral Fellow
Department of Biostatistics & Health Data Science
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users.
We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
Dr. Dehghani[/caption]
MedicalResearch.com Interview with:
Ali Dehghani, DO
Department of Medicine
University Hospitals Cleveland Medical Center / Case Western Reserve University
Presenting Author, IDWeek 2025
MedicalResearch.com: What is the background for this study?
Response: Shingles (herpes zoster) is caused by reactivation of the varicella-zoster virus, which can inflame blood vessels and the nervous system. Evidence over the past decade has linked shingles to higher risks of heart attack, stroke, and dementia—but it was unclear whether the shingles vaccine might lessen those long-term effects.
[caption id="attachment_71061" align="aligncenter" width="500"]
Clubfoot
Clubfoot
Dr. Jiyoung Ahn[/caption]
MedicalResearch.com Interview with:
Jiyoung Ahn, PhD
Dr. King[/caption]
Brett King, MD, PHD
Dr. King was named an American Academy of Dermatology (AAD) “Patient Care Hero”
for his work treating patients with severe alopecia areata
Dermatology Physicians of Connecticut
Fairfield, Connecticut
MedicalResearch.com: What is the background for this study? Would you briefly explain the condition of Alopecia Areata?
Response: Alopecia Areata (AA), an autoimmune form of hair loss, is common and its treatment has been revolutionized in the past ~3 years with approvals of 3 JAK inhibitors, bariticinib, ritlecitinib and deuruxolitinib. Prior to these approvals, off label treatments included the JAK inhibitors tofacitinib and ruxolitinib.
Dr. Casale[/caption]
Thomas B. Casale, M.D.
Professor of Medicine and Pediatrics
Chief of Clinical and Translational Research
Division of Allergy and Immunology
USF Health Morsani College of Medicine
University of South Florida
Tampa, Florida
MedicalResearch.com: What is the background for this study?
Response: The data leading to FDA approval of neffy came from extensive pharmacokinetic and pharmacodynamic studies. As with previous epinephrine delivery devices, the FDA asked for data showing that after delivery of neffy the epinephrine blood levels and expected changes in pulse and blood pressure were similar to those achieved with injectable formulations of epinephrine. neffy performed as expected with blood levels of epinephrine bracketed by those achieved with EpiPen and a needle and syringe along with increases in pulse and blood pressure compatible with the epinephrine levels measured.
Additionally, clinicians are interested in whether neffy would perform similarly in real clinical situations. The data from the neffy experience program provides real-world assurance that neffy can effectively treat acute allergic reactions. Given the large number of patients and the similar findings to those achieved with injectable epinephrine in previous studies, the data should provide assurance that neffy can be an effective substitute for injectable epinephrine in patients that desire a needle-free option.
